F508del-CFTR Rescue: A matter of cell stress response

Current Pharmaceutical Design

Volumn 19, Issue 19, 2013, Pages 3476-3496

  Nieddu, Erika ^a   Pollarolo, Benedetta ^a   Merello, Luisa ^b   Schenone, Silvia ^a   Mazzei, Mauro ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Cell stress response; Chaperones; Cold shock induced proteins; F508del CFTR; Heat shock proteins; Hsc70; Hsp70; Osmolytes

Indexed keywords

ALANINE; ARGININE; BETAINE; CHAPERONE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DIMETHYL SULFOXIDE; ECTOINE; GLYCEROL; GLYCEROPHOSPHORYLCHOLINE; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; INOSITOL; MANNITOL; MANNOSE; MATRINE; PROLINE; PROTEIN; SARCOSINE; SORBITOL; TAURINE; TREHALOSE; TRIMETHYLAMINE OXIDE; 4 PHENYLBUTYRIC ACID; 4-PHENYLBUTYRIC ACID; ALKALOID; ARYLBUTYRIC ACID DERIVATIVE; CURCUMIN; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR DELTA F508; QUINOLIZINE DERIVATIVE;

CELL MATURATION; CELL STIMULATION; CELL STRUCTURE; CELLULAR STRESS RESPONSE; COLD; CYSTIC FIBROSIS; DOWN REGULATION; ENZYME INHIBITION; FEEDBACK SYSTEM; GENE MUTATION; HUMAN; HYPOTHERMIA; LOW TEMPERATURE; NONHUMAN; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; UPREGULATION; WILD TYPE; ANIMAL; CELL MEMBRANE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PROTEIN DOMAIN; PROTEIN TRANSPORT;

ALKALOIDS; ANIMALS; CELL MEMBRANE; COLD TEMPERATURE; CURCUMIN; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PHENYLBUTYRATES; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN TRANSPORT; QUINOLIZINES;

EID: 84887384484     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990317     Document Type: Review

References (123)

1. Sheppard DN, Welsh MJ. Structure and Function of the CFTR Chloride Channel. Physiol Rev 1999; 79: S23-S45.
2. Bernard K, Kirk KL. Cross-linking of ΔF508-CFTR promotes its trafficking to the plasma membrane. Channels 2010; 4: 251-4.
3. Heda GD, Tanwani M, Marino CR. The Delta F508 mutation shortens the biochemical half-life of plasma membrane CFTR in polarized epithelial cells. Am J Physiol Cell Physiol 2001; 280: C166-74.
4. Brown CR, Hong-Brown LQ, Welch WJ. Strategies for correcting the delta F508 CFTR protein-folding defect. J Bioenerg Biomembr 1997; 29: 491-502.
5. Becq F, Mall MA, Sheppard DN, Conese M, Zegarra-Moran O. Pharmacological therapy for cystic fibrosis: from bench to bedside. J Cyst Fibros 2011; 10(Suppl 2): S129-45.
6. Sondo E, Tomati V, Caci E, et al. Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling. Am J Physiol Cell Physiol 2011; 301: C872-85.
7. Denning GM, Anderson MP, Amara JF, Marshall J, Smith AE, and Welsh MJ. Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. Nature 1992; 358: 761-4.
8. Choo-Kang LR, Zeitlin PL. Induction of HSP70 promotes DF508 CFTR trafficking. Am J Physiol Lung Cell Mol Physiol 2001; 281: L58-L68.
9. Pedemonte N, Diena T, Caci E, et al. Antihypertensive 1,4-Dihydropyridines as Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator Channel Gating Defect Caused by Cystic Fibrosis Mutations. Mol Pharmacol 2005; 68: 1736-46.
10. Pedemonte N, Lukacs GL, Du K, et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by highthroughput screening. J Clin Invest 2005; 115: 2564-71.
11. Vij N. (2010, June 23). CFTR Proteostasis: Mechanisms and Therapeutic Strategies. SciTopics. Retrieved June 7, 2012, Available from http://www.scitopics.com/CFTR_Proteostasis_Mechanisms_ and_Therapeutic_Strategies.html
12. Bukau B, Weissman J, Horwich A. Molecular chaperones and protein quality control. Cell 2006; 125: 443-51.
13. Riordan JR. CFTR function and prospects for therapy. Annu Rev Biochem 2008; 77: 701-26.
14. Hoelen H, Kleizen B, Schmidt A, et al. The primary folding defect and rescue of ΔF508 CFTR emerge during translation of the mutant domain. PLoS One 2010; 5(11): e15458.
15. Basile A, Pascale M, Franceschelli S, et al. Matrine Modulates HSC70 Levels and Rescues ΔF508-CFTR. J Cell Physiol 2012; 227: 3317-23.
16. Scott-Ward TS, Amaral MD. Deletion of Phe508 in the first nucleotide-binding domain of the cystic fibrosis transmembrane conductance regulator increases its affinity for the heat shock cognate 70 chaperone. FEBS J 2009; 276: 7097-109.
17. Fan CY, Lee S, Cyr DM. Mechanisms for regulation of Hsp70 function by Hsp40. Cell Stress Chaperones 2003; 8(4): 309-16.
18. Matsumura Y, David LL, Skach WR. Role of Hsc70 binding cycle in CFTR folding and endoplasmic reticulum-associated degradation. Mol Biol Cell 2011; 22: 2797-809.
19. Meacham GC, Patterson C, Zhang W, Younger JM, Cyr DM. The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Nat Cell Biol 2001; 3: 100-5.
20. Okiyoneda T, Barrière H, Bagdány M, et al. Peripheral protein quality control removes unfolded CFTR from the plasma membrane. Science 2010; 329: 805-10.
21. Katschinski DM. On Heat and Cells and Proteins. News Physiol Sci 2004; 19 (1): 11-5.
22. Available at http://www.genecards.org
23. Sharma D, Masison DC. Hsp70 Structure, Function, Regulation and Influence on Yeast Prions. Protein Pept Lett 2009; 16: 571-81.
24. Mayer MP, Bukau B. Hsp70 chaperones: cellular functions and molecular mechanism. Cell Mol Life Sci 2005; 62: 670-84.
25. Brocchieri L, Conway de Macario E, Macario AJ. hsp70 genes in the human genome: Conservation and differentiation patterns predict a wide array of overlapping and specialized functions. BMC Evol Biol 2008; 8: 19.
26. Tavaria M, Gabriele T, Kola I, Anderson RL. A hitchhiker's guide to the human Hsp70 family. Cell Stress Chaperones 1996; 1: 23-8.
27. Callahan MK, Chaillot D, Jacquin C, Clark PR, Ménoret A. Differential acquisition of antigenic peptides by Hsp70 and Hsc70 under oxidative conditions. J Biol Chem 2002; 277: 33604-9.
28. Rubenstein RC, Zeitlin PL. Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTR. Am J Physiol Cell Physiol 2000; 278: C259-67.
29. Aquino DA, Lopez C, Farooq M. Antisense oligonucleotide to the 70-kDa heat shock cognate protein inhibits synthesis of myelin basic protein. Neurochem Res 1996; 21: 417-22.
30. Garcia-Bermejo L, Vilaboa NE, Perez C, Galan A, De Blas E, Aller P. Modulation of heat-shock protein 70 (HSP70) gene expression by sodium butyrate in U-937 promonocytic cells: relationships with differentiation and apoptosis. Exp Cell Res 1997; 236: 268-74.
31. Srivastava M, Eidelman O, Pollard HB. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis. Mol Med 1999; 5: 753-67.
32. Teiten MH, Reuter S, Schmucker S, Dicato M, Diederich M. Induction of heat shock response by curcumin in human leukemia cells. Cancer Lett 2009; 279: 145-54.
33. Khan S, Heikkila JJ. Curcumin-induced inhibition of proteasomal activity, enhanced HSP accumulation and the acquisition of thermotolerance in Xenopus laevis A6 cells. Comp Biochem Physiol A Mol Integr Physiol 2011; 158: 566-76.
34. Cho HJ, Gee HY, Baek KH, et al. A small molecule that binds to an ATPase domain of Hsc70 promotes membrane trafficking of mutant cystic fibrosis transmembrane conductance regulator. J Am Chem Soc 2011; 133(50): 20267-76.
35. Fewell SW, Day BW, Brodsky JL. Identification of an inhibitor of hsc70-mediated protein translocation and ATP hydrolysis. J Biol Chem 2001; 276(2): 910-4.
36. Nadler SG, Dischino DD, Malacko AR, Cleaveland JS, Fujihara SM, Marquardt H. Identification of a binding site on Hsc70 for the immunosuppressant 15-deoxyspergualin. Biochem Biophys Res Commun 1998; 253: 176-80.
37. Chanoux RA, Rubenstein RC. Molecular chaperones as targets to circumvent the CFTR defect in Cystic Fibrosis. Front Pharmacol 2012; 3: 137.
38. Goldfarb SB, Kashlan OB, Watkins JN, et al. Differential effects of Hsc70 and Hsp70 on the intracellular trafficking and functional expression of epithelial sodium channels. Proc Natl Acad Sci USA 2006; 103: 5817-22.
39. Didenko T, Duarte AM, Karagöz GE, Rüdiger SG. Hsp90 structure and function studied by NMR spectroscopy. Biochim Biophys Acta 2012; 1823: 636-47.
40. Coppinger JA, Hutt DM, Razvi A, et al. A Chaperone Trap Contributes to the Onset of Cystic Fibrosis. PLoS One 2012; 7(5): e37682.
41. Fuller W, Cuthbert AW. Post-translational disruption of the delta F508 cystic fibrosis transmembrane conductance regulator (CFTR)-molecular chaperone complex with geldanamycin stabilizes delta F508CFTR in the rabbit reticulocyte lysate. J Biol Chem 2000; 275: 37462-8.
42. Chen B, Piel WH, Gui L, Bruford E, Monteiro A. The HSP90 family of genes in the human genome: insights into their divergence and evolution. Genomics 2005; 86(6): 627-37.
43. Bidoia C. Human T-lymphotropic virus proteins and posttranslational modification pathways. World J Virol 2012; 1(4): 115-30.
44. Tsutsumi S, Mollapour M, Prodromou C, et al. Charged linker sequence modulates eukaryotic heat shock protein 90 (Hsp90) chaperone activity. Proc Natl Acad Sci USA 2012; 109: 2937-42.
45. Roy KK, Singh S, Saxena AK. Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anticancer agents: 3D-QSAR study. Mol Divers 2011; 15: 477-89.
46. Chiosis G, Caldas Lopes E, Solit D. Heat shock protein-90 inhibitors: a chronicle from geldanamycin to today's agents. Curr Opin Investig Drugs 2006; 7(6): 534-41.
47. Goetz MP, Toft DO, Ames MM, Erlichman C. The Hsp90 chaperone complex as a novel target for cancer therapy. Ann Oncol 2003; 14(8): 1169-76.
48. Meyer P, Prodromou C, Hu B, et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 2003; 11: 647-58.
49. Söti C, Rácz A, Csermely P. A Nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. Nterminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 2002; 277: 7066-75.
50. Li J, Soroka J, Buchner J. The Hsp90 chaperone machinery: Conformational dynamics and regulation by co-chaperones. Biochim Biophys Acta 2012; 1823: 624-35.
51. Howard M, Fischer H, Roux J, et al. Mammalian Osmolytes and SNitrosoglutathione Promote ΔF508 Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein Maturation and Function. J Biol Chem 2003; 278: 35159-67.
52. Snyder AH, McPherson ME, Hunt JF, Johnson M, Stamler JS, Gaston B. Acute effects of aerosolized S-nitrosoglutathione in cystic fibrosis. Am J Respir Crit Care Med 2002; 165: 922-6.
53. Jain L, Chen XJ, Brown LA, Eaton DC. Nitric oxide inhibits lung sodium transport through a cGMP-mediated inhibition of epithelial cation channels. Am J Physiol 1998; 274: L475-84.
54. Hudson VM. Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 2001; 30: 1440-61.
55. Brown CR, Hong-Brown LQ, Biwersi J, Verkman AS, Welch WJ. Chemical chaperones correct the mutant phenotype of the F508 cystic fibrosis transmembrane conductance regulator protein. Cell Stress Chaperones 1996; 1: 117-25.
56. Bai CX, Biwersi J, Verkman AS, Matthay MA. A mouse model to test the in vivo efficacy of chemical chaperones. J Pharmacol Toxicol Methods 1998; 40: 39-45.
57. Fischer H, Fukuda N, Barbry P, Illek B, Sartori C, Matthay MA. Partial restoration of defective chloride conductance in DeltaF508 CF mice by trimethylamine oxide. Am J Physiol Lung Cell Mol Physiol 2001; 281: L52-7.
58. Hawthorne DC, Friis J. Osmotic-remedial mutants. a new classification for nutritional mutants in yeast. Genetics 1964; 50: 829-39.
59. Arakawa T, Timasheff SN. The stabilization of proteins by osmolytes. Biophys J 1985; 47: 411-4.
60. Arakawa T, Ejima D, Kita Y, Tsumoto K. Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochim Biophys Acta 2006; 1764: 1677-87.
61. Lentzen G, Schwarz T. Extremolytes: natural compounds from extremophiles for versatile applications. Appl Microbiol Biotechnol 2006; 72: 623-34.
62. Johnston JA, Ward CL, Kopito RR. Aggresomes: a cellular response to misfolded proteins. J Cell Biol 1998; 143: 1883-98.
63. Luciani A, Villella VR, Esposito S, et al. Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition. Nat Cell Biol 2010; 12: 863-75.
64. Yancey PH, Clark ME, Hand SC, Bowlus RD, Somero GN. Living with water stress: evolution of osmolyte systems. Science 1982; 217: 1214-22.
65. Garcia-Perez A, Burg MB. Renal medullary organic osmolytes. Physiol Rev 1991; 71: 1081-115.
66. IPCS inchem database. Available from: http://www.inchem.org
67. Directive 67/548/EEC Available from: http://eur-lex.europa.eu/Lex UriServ/LexUriServ.do?uri=CELEX:31967L0548:EN:HTML
68. Sigma Datasheet. Available from: http://www.sigma-aldrich.com
69. Merck datasheet Available from: http://www.merckmillipore.com
70. ScienceLab Datasheet Available from: http://www.ScienceLab.com
71. Oku T, Okazaki M. Transitory laxative threshold of trehalose and lactulose in healthy women. J Nutr Sci Vitaminol (Tokyo) 1998; 44: 787-98.
72. 2001/721/CE Available from: http://eur-lex.europa.eu/LexUriServ/ LexUriServ.do?uri=OJ:L:2001:269:0017:0019:EN:PDF
73. Nakamura S, Oda Y, Ugawa M. Induction of umu gene expression in Salmonella typhimurium TA1535/pSK1002 by Dimethyl sulfoxide (DMSO). Mutat Res 1990; 229: 11-5.
74. Santos NC, Figueira-Coelho J, Martins-Silva J, Saldanha C. Multidisciplinary utilization of dimethyl sulfoxide: pharmacological, cellular, and molecular aspects. Biochem Pharmacol 2003; 65: 1035-41.
75. Chow FC, Dysart MI, Hamar DW, Lewis LD, Udall RH. Alanine: a toxicity study. Toxicol Appl Pharmacol 1976; 37: 491-7.
76. Green TR, Fellman JH, Eicher AL, Pratt KL. Antioxidant role and subcellular location of hypotaurine and taurine in human neutrophils. Biochim Biophys Acta 1991; 1073: 91-7.
77. Zhang M, Izumi I, Kagamimori S, et al. Role of taurine supplementation to prevent exercise-induced oxidative stress in healthy young men. Amino Acids 2004; 26: 203-207.
78. Scientific Opinion of the Panel on Food Additives and Nutrient Sources added to Food on a request from the Commission on the use of taurine and D-glucurono-γ-lactone as constituents of the so called "energy" drinks. EFSA J 2009; 935: 1-31.
79. Tsubuku S, Hatayama K, Mawatari K, Smriga M, Kimura T. Thirteen-week oral toxicity study of L-arginine in rats. Int J Toxicol 2004; 23: 101-5.
80. Bednarz B, Wołk R, Chamiec T, Ceremuzyński L. Prognostic value of exercise-induced QT dispersion in patients after acute myocardial infarction. Kardiol Pol 2004; 61: 442-50.
81. Rector TS, Bank AJ, Mullen KA, et al. Randomized, double-blind, placebo-controlled study of supplemental oral L-arginine in patients with heart failure. Circulation 1996; 93: 2135-41.
82. Ceremuzyński L, Chamiec T, Herbaczyńska-Cedro K. Effect of supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris. Am J Cardiol 1997; 80: 331-3.
83. Adams MR, McCredie R, Jessup W, Robinson J, Sullivan D, Celermajer DS. Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 1997; 129(2): 261-9.
84. Blum A, Miller H, Blum A, Miller H. The effects of L-arginine on atherosclerosis and heart disease. Int J Cardiovasc Intervent 1999; 2: 97-100.
85. N-methylglycine (Sarcosine) Treatment for Depression. Available from http://www.clinicaltrials.gov
86. Tsai G, Lane H, Yang P, Chong M, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry 2004; 55: 452-6.
87. Sreekumar A, Poisson LM, Rajendiran TM et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-4.
88. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 2010; 47(Pt 3): 282.
89. Klein J, Schwarz T, Lentzen G. Ectoine as a natural component of food: detection in red smear cheeses. J Dairy Res 2007; 74(4): 446-51.
90. Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to an application concerning the use of betaine as a novel food in the EU. EFSA J 2005; 191: 1-17.
91. Kawamura T, Okubo T, Sato K, Fujita S, Goto K, Hamaoka T, Iemitsu M. Glycerophosphocholine enhances growth hormone secretion and fat oxidation in young adults. Nutrition 2012; Available from http://dx.doi.org/10.1016/j.nut.2012.02.011
92. Barbagallo Sangiorgi G, Barbagallo M, Giordano M, Meli M, Panzarasa R. Alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks. An Italian multicenter clinical trial. Ann N Y Acad Sci 1994; 717: 253-69.
93. Brownawell AM, Carmines EL, Montesano F. Safety assessment of AGPC as a food ingredient. Food Chem Toxicol 2011; 49(6): 1303-15.
94. O'Connell GD, Fong JV, Dunleavy N, Joffe A, Ateshian GA, Hung CT. Trimethylamine N-oxide as a media supplement for cartilage tissue engineering. J Orthop Res 2012; doi: 10.1002/jor.22171.
95. Seibel BA, Walsh PJ. Trimethylamine oxide accumulation in marine animals: relationship to acylglycerol storage. J Exp Biol 2002; 205(Pt 3): 297-306.
96. Bain MA, Faull R, Fornasini G, Milne RW, Evans AM. Accumulation of trimethylamine and trimethylamine-N-oxide in end-stage renal disease patients undergoing haemodialysis. Nephrol Dial Transplant 2006; 21(5): 1300-4.
97. Fischer H, Schwarzer C, Illek B. Vitamin C controls the cystic fibrosis transmembrane conductance regulator chloride channel. Proc Natl Acad Sci USA 2004; 101(10): 3691-6.
98. Trimethylamine N-oxide datasheet. Available from http://datasheets.scbt.com/sc-253763.pdf
99. Morello JP, Petäjä-Repo UE, Bichet DG, Bouvier M. Pharmacological chaperones: a new twist on receptor folding. Trends Pharmacol Sci 2000; 21: 466-9.
100. Cohen FE, Kelly JW. Therapeutic approaches to protein-misfolding diseases. Nature 2003; 426: 905-9.
101. Gekko K, Timasheef SN. Mechanism of protein stabilization by glycerol: preferential hydration in glycerol water mixtures. Biochemistry 1981; 20: 4667-76.
102. Gekko K, Timasheef SN. Thermodynamic and kinetic examination of protein stabilization by glycerol. Biochemistry 1981; 20: 4677-86.
103. Sato S, Ward CL, Krouse ME, Wine JJ, Kopito RR. Glycerol reverses the misfolding phenotype of the most common cystic fibrosis mutation. J Biol Chem 1996; 271: 635-8.
104. Buommino E, Schiraldi C, Baroni A, et al. Ectoine from halophilic microorganisms induces the expression of hsp70 and hsp70B' in human keratinocytes modulating the proinflammatory response. Cell Stress Chaperones 2005; 10: 197-203.
105. Boutilier RG. Mechanisms of cell survival in hypoxia and hypothermia. J Exp Biol 2001; 204: 3171-81.
106. Plesnila N, Muller E, Guretzki S, Ringel F, Staub F, Baethmann A. Effect of hypothermia on the volume of rat glial cells. J Physiol 2000; 523: 155-62.
107. Sonna LA, Fujita J, Gaffin SL, Lilly CM. Invited Review: Effects of heat and cold stress on mammalian gene expression. J Appl Physiol 2002; 92: 1725-42.
108. Chaikam V, Karlson DT. Comparison of structure, function and regulation of plant cold shock domain proteins to bacterial and animal cold shock domain proteins. BMB Reports 2010; 43(1): 1-8.
109. Graumann PL, Marahiel MA. A superfamily of proteins that contain the cold-shock domain. Trends Biochem Sci 1998; 23: 286-90.
110. Woo SK, Lee SD, Na KY, Park WK, Kwon HM. TonEBP/NFAT5 stimulates transcription of HSP70 in response to hypertonicity. Mol Cell Biol 2002; 22: 5753-60.
111. Mahajan S, Tuteja N. Cold, salinity and drought stresses: An overview. Arch Biochem Biophys 2005; 444: 139-58
112. Eliseeva IA, Kim ER, Guryanov SG, Ovchinnikov LP, Lyabin DN. Y-box-binding protein 1 (YB-1) and its functions. Biochemistry (Mosc) 2011; 76(13): 1402-33.
113. Kohno K, Izumi H, Uchiumi T, Ashizuka M, Kuwano M. The pleiotropic functions of the Y-box-binding protein, YB-1. Bioessays 2003; 25: 691-8.
114. Kloks CP, Spronk CA, Lasonder E, et al. The solution structure and DNA-binding properties of the cold-shock domain of the human Ybox protein YB-1. J Mol Biol 2002; 316: 317-26.
115. Ohashi S, Atsumi M, Kobayashi S. HSP60 interacts with YB-1 and affects its polysome association and subcellular localization. Biochem Biophys Res Commun 2009; 385: 545-50.
116. + transport of V79 fibroblasts. J Cell Physiol 1990; 144: 216-21.
117. Gaffin SL, Koratich M, Hubbard RW. The effect of hyperthermia on intracellular sodium concentrations of isolated human cells. Ann N Y Acad Sci 1997; 813: 637-9.
118. Amorino GP, Fox MH. Effects of hyperthermia on intracellular chloride. Journal of Membrane Biology 1996; 152 (3): 217-22.
119. Prohászka Z, Füst G. Immunological aspects of heat-shock proteins-the optimum stress of life. Mol Immunol 2004; 41: 29-44.
120. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol 2007; 81: 15-27.
121. Srivastava PK, Menoret A, Basu S, Binder RJ, McQuade KL. Heatshock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 1998; 8: 657-65.
122. Asea A. Heat shock proteins and toll-like receptors. Handb Exp Pharmacol 2008; 183: 111-27.
123. Nieddu E, Pasa S. Interfering with Protein-Protein Contact: Molecular Interaction Maps and Peptide Modulators. Curr Topics Med Chem 2007; 7: 21-32.